Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs
Aur surges as a highly promising anticancer drug, suggesting that efforts to establish this drug in the clinical treatment protocols are warranted and worthy to undertake.
Authors
- Sara Rodríguez‐Enríquez (ORCID: https://orcid.org/0000-0002-0822-1233)
- Rafael Moreno‐Sánchez (ORCID: https://orcid.org/0000-0002-9587-7184)
- Silvia Cecilia Pacheco-Velázquez (ORCID: https://orcid.org/0000-0002-6772-6389)
- Tuuli Käämbre (ORCID: https://orcid.org/0000-0001-5755-4694)
- Joaquín Alberto Padilla-Flores
- Jorge Luis Vargas-Navarro
- Diana Xochiquetzal Robledo‐Cadena (ORCID: https://orcid.org/0000-0002-7287-938X)
Institutions
- Universidad Autónoma de Tlaxcala (MX)
- Oregon Health & Science University (US)
- National Institute of Chemical Physics and Biophysics (EE)
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1371/journal.pone.0309331
- Citations
- 3
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- Keemilise ja Bioloogilise Füüsika Instituut
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México